Press Release Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress Aug 5
Press Release Lilly’s olomorasib receives U.S. FDA’s Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer Aug 3
Press Release Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Jul 23